{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:10:42Z","timestamp":1777349442076,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clim.2019.108307","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T02:51:59Z","timestamp":1574304719000},"page":"108307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies"],"prefix":"10.1016","volume":"210","author":[{"given":"J.","family":"Ochoa-Grull\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Benavente Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"P\u00e9rez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pe\u00f1a Cortijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodr\u00edguez de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"\u00c1lvarez Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mateo Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Llano-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rodr\u00edguez de Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Guevara-Hoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cordero Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Orte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fern\u00e1ndez-Arquero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fern\u00e1ndez-Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Serrano-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Recio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"P\u00e9rez de Diego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"S\u00e1nchez-Ram\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2019.108307_bb0005","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.clim.2019.108307_bb0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment: chronic lymphocytic leukemia","volume":"90","author":"Hallek","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2019.108307_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00317","article-title":"Challenges in the role of Gammaglobulin replacement therapy and vaccination strategies for hematological malignancy","volume":"7","author":"S\u00e1nchez-Ram\u00f3n","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.clim.2019.108307_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin. Lymphoma Myeloma."},{"key":"10.1016\/j.clim.2019.108307_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica."},{"key":"10.1016\/j.clim.2019.108307_bb0040","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood."},{"key":"10.1016\/j.clim.2019.108307_bb0045","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","article-title":"Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy","volume":"100","author":"Visentin","year":"2015","journal-title":"Haematologica."},{"key":"10.1016\/j.clim.2019.108307_bb0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.02.011","article-title":"Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage a chronic lymphocytic leukemia","volume":"57","author":"Mauro","year":"2017","journal-title":"Leuk. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2019.108307_bb0055","first-page":"17","article-title":"Intravenous immune globulin in chronic lymphocytic leukaemia","volume":"97","author":"Gamm","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach: when to initiate IgG therapy in antibody deficiency","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2018.05.013","article-title":"Measurement and interpretation of Salmonella typhi vi IgG antibodies for the assessment of adaptive immunity","volume":"459","author":"Parker","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2019.108307_bb0070","unstructured":"European Medicines Agency, Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg), 2019. (n.d.) 12."},{"key":"10.1016\/j.clim.2019.108307_bb0075","unstructured":"G. Lee, N. Bennett, P. Hunter, T. Mongeau, L. Lee, T. Pilishvili, A. Matanock, L. Rubin, M. Sawyer, R. Zimmerman, J. Zucker, W. Schaffner, M. Farley, J. Duchin, K. Klugman, G. Foundation, K. Neuzil, A. Reingold, K. Talbot, Pneumococcal Vaccines Work Group Members, (n.d.) 9."},{"key":"10.1016\/j.clim.2019.108307_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00654","article-title":"Measurement of Typhim vi IgG as a diagnostic tool to determine anti-polysaccharide antibody production deficiency in children","volume":"10","author":"Guevara-Hoyer","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2017.e00333","article-title":"The response to Typhi vi vaccination is compromised in individuals with primary immunodeficiency","volume":"3","author":"Kumarage","year":"2017","journal-title":"Heliyon."},{"key":"10.1016\/j.clim.2019.108307_bb0090","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.clim.2019.108307_bb0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2249.2004.02439.x","article-title":"Development of an anti-Salmonella typhi vi ELISA: assessment of immunocompetence in healthy donors","volume":"136","author":"Ferry","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the american academy of allergy, asthma & immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clim.2016.05.006","article-title":"Multicenter study for the evaluation of the antibody response against salmonella typhi vi vaccination (EMPATHY) for the diagnosis of anti -polysaccharide antibody production deficiency in patients with primary immunodeficiency","volume":"169","author":"S\u00e1nchez-Ram\u00f3n","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0110","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia","volume":"319","author":"A Randomized, Controlled Clinical Trial Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2019.108307_bb0115","first-page":"S1","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"94","author":"Bonilla","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0120","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet."},{"key":"10.1016\/j.clim.2019.108307_bb0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2017.06.009","article-title":"Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders","volume":"141","author":"Hauck","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.clim.2019.108307_bb0135","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1002\/anie.200901917","article-title":"The search for infectious causes of human cancers: where and why (Nobel lecture)","volume":"48","author":"zur Hausen","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.clim.2019.108307_bb0140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10875-017-0406-6","article-title":"The use of Salmonella Typhim vaccine to diagnose antibody deficiency","volume":"37","author":"Bausch-Jurken","year":"2017","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2019.108307_bb0145","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cei.13105","article-title":"Measurement of Typhi vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency: use of Typhi vi in immunodeficiency","volume":"192","author":"Evans","year":"2018","journal-title":"Clin. Exp. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161930261X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161930261X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:00:20Z","timestamp":1761494420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166161930261X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"alternative-id":["S152166161930261X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.108307","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.108307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108307"}}